MedTrace Logo

Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal

NCT03767946 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-07-28

No results posted yet for this study

Summary

A cross-sectional childhood M. tuberculosis infection survey of age-specific rates (defined by positivity to the test QuantiFERON-TB Gold Plus) will be conducted in Senegal to collect information on the local TB endemic to inform site selection, sample size, and recruitment strategies for a future efficacy trial of vaccine candidate MTBVAC in young children.

Conditions

Interventions

DIAGNOSTIC_TEST

Quantiferon Gold Plus Test

Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.

Sponsors & Collaborators

  • Biofabri, S.L

    collaborator INDUSTRY

  • TuBerculosis Vaccine Initiative

    collaborator OTHER

  • Universidad de Zaragoza

    collaborator OTHER

  • University of Cape Town

    collaborator OTHER

  • Institut Pasteur de Madagascar

    collaborator OTHER

  • Biomedical Research Center EPLS

    lead OTHER

Principal Investigators

  • Amadou T LY · Biomedical Research Center EPLS

Eligibility

Min Age
11 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-27
Primary Completion
2020-12-20
Completion
2022-07-27

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03767946 on ClinicalTrials.gov